Unfortunately, Candida auris , a drug-resistant fungus capable of spreading through hospitals, surviving on surfaces and colonising patients without causing obvious symptoms, is very real.
Often described in headlines as a “superbug fungus,” Candida auris – also known as Candidozyma auris – has become an increasingly important infection-control challenge for hospitals and long-term healthcare facilities.
The fungus was first identified in 2009. Since then, it has spread internationally and established itself as an emerging healthcare-associated pathogen.
Recent figures from the United States illustrate how quickly the problem has grown.
According to the U.S. Centers for Disease Control and Prevention (CDC), 6,304 clinical cases of C. auris were reported in the United States during 2024. The number of reported clinical cases has increased every year since the first U.S. case was reported in 2016, although the CDC says the rate of increase has slowed since 2022.
C. auris predominantly threatens people who are already seriously ill, particularly patients requiring complex healthcare or invasive medical devices.
But for hospital administrators, laboratory managers, microbiologists and infection-prevention teams, the recent increase of C. auris cases raises a much more important question:
How quickly could your healthcare facility identify a patient carrying Candida auris before that patient contributes to wider transmission?
This is where molecular diagnostics; particularly rapid screening, become increasingly relevant.
What Is the ‘Superbug’ Fungus Candida Auris?

Candida auris is a yeast, a type of fungus.
It can colonise people without causing symptoms, but it can also cause serious invasive infections including bloodstream infections.
The CDC describes C. auris as an emerging fungus capable of causing life-threatening, often multidrug-resistant infections. It primarily affects seriously ill or immunocompromised patients and can spread efficiently within healthcare environments.
Bosch’s Vivalytic clinical material similarly describes C. auris as a fungal pathogen capable of causing severe infections, particularly among vulnerable patients with serious underlying medical conditions in hospitals and long-term care facilities.
This combination of characteristics explains why C. auris has attracted so much attention.
It can be:
- difficult to identify;
- difficult to treat;
- capable of surviving in healthcare environments;
- and capable of spreading from patients who do not appear infected.
1. Why Is Candida Auris Called a “Superbug”?
The word superbug is an informal term rather than a precise taxonomic classification. It is usually used to describe microorganisms that have developed resistance to medicines commonly used to treat them.
Most discussion of superbugs concerns antibiotic-resistant bacteria.
But C. auris is different.
It is a fungus, so antibiotics are not the relevant treatment. The concern is antifungal resistance.
The situation is evolving further.
In its February 2026 clinical update, the CDC reported increasing numbers of echinocandin-resistant and pan-resistant C. auris cases in the United States, including outbreaks involving people with overlapping healthcare exposures.
This is why the phrase “superbug fungus Candida auris” has become increasingly common.
The problem is not simply that the organism can cause infection.
It is that some infections can become particularly difficult to treat.
2. Is Candida Auris Dangerous to Everyone?
No.
This distinction is important because alarming headlines can create the impression that C. auris represents the same level of risk to everyone.
It does not.
According to the CDC, C. auris predominantly affects patients who require complex medical care, particularly those with:
- prolonged or frequent healthcare stays;
- severe underlying medical conditions;
- ventilators or breathing tubes;
- central venous catheters;
- feeding tubes;
- urinary catheters;
- or other invasive medical devices.
People without these risk factors generally have a low risk of becoming infected or colonised.
So this is not primarily a situation in which healthy people should fear ordinary day-to-day contact.
It is first and foremost a healthcare infection-control problem.
And that makes rapid identification particularly important.
3. Candida Auris Can Spread Without Making Someone Obviously Ill

One of the most important things to understand about C. auris is the difference between infection and colonisation.
- A patient with an active infection may become seriously ill.
- A colonised patient may have C. auris living on their skin or elsewhere on their body while experiencing no symptoms at all.
But absence of symptoms does not necessarily mean absence of transmission risk.
The CDC warns that colonised patients can shed the organism onto surrounding surfaces and objects, potentially allowing it to reach other patients.
This creates a major infection-control problem.
You cannot reliably identify every person carrying C. auris simply by looking for sick patients.
Some carriers may look perfectly well.
That is why screening matters.
4. Candida Auris Can Persist on Healthcare Surfaces
An infected or colonised patient can contaminate objects and surfaces around them such as:
- bedrails;
- bedside tables;
- doorknobs;
- blood-pressure equipment;
- glucometers;
- ultrasound machines;
- and other mobile medical equipment.
Why Screening Is So Important for Candida Auris

The CDC describes screening for C. auris colonisation as a key strategy for preventing transmission and outbreaks in healthcare facilities.
Screening may help identify people carrying the organism before symptoms appear, or even when symptoms never develop.
That allows infection-control teams to consider appropriate precautions earlier.
The CDC also says healthcare facilities may use screening in different circumstances, including:
- on admission, where appropriate, to identify patients bringing C. auris into a facility;
- during a healthcare stay, particularly where transmission is suspected;
- and in connection with discharge or transfer, where results may help receiving facilities implement appropriate precautions.
Screening strategies should not simply be applied indiscriminately, and it is recommended that decisions take account of local epidemiology, patient risk factors, epidemiological links, healthcare setting and the purpose of the screening programme.
How Does the Bosch Vivalytic Candida Auris Test Work?

The Vivalytic C. auris test is a qualitative real-time PCR assay designed to detect Candida auris.
According to the Bosch product material supplied to MediDiagAfrica, the assay targets the ITS2 gene and provides a result in approximately 60 minutes.
Vivalytic C. Auris ( At a Glance )
| Specification | Vivalytic C. auris |
|---|---|
| Detected Pathogen | Candida auris |
| Molecular Target | ITS2 gene |
| Detection Method | Real-time PCR |
| Time-to-Result | Approx. 60 minutes |
| Sample Volume | 300 µL per test |
| Sample Material | Axilla/groin/nasal combination swabs; nasal swabs |
| Transport Medium | Liquid Amies |
| System Type | Highly automated molecular diagnostic workflow |
Bosch states that Vivalytic provides highly specific detection of C. auris through the ITS2 target and supports nasal samples as well as composite axilla/groin samples in combination with nasal swabs.
The system is also designed as a point-of-need solution with only a few steps from sample to result. Bosch states that the workflow requires no additional laboratory equipment and no specimen transport when testing is performed where the system is located.
- That last point deserves attention because for some hospitals, the major advantage of molecular testing may not simply be the PCR reaction time.
- It may be removing hours or even days from sample transportation, external processing and result reporting.
The Financial Cost of a Candida Auris Outbreak Can Be Enormous

This connects directly to a broader issue we examined in our MediDiagAfrica article on the cost of infectious-disease outbreaks.
Bosch’s model estimates the following:
| Potential Outbreak Impact | Bosch Modelled Estimate |
|---|---|
| Additional staff workload | ~175 hours per case |
| Hygiene measures | ~€11,000 per case |
| Additional hospital stay | ~53 days per patient |
| Total financial impact | ~€115,000 per case |
Once C. auris transmission becomes established within a healthcare facility, the costs can extend far beyond testing.
Hospitals may face:
- additional staff workload;
- patient isolation;
- specialised cleaning;
- environmental decontamination;
- contact screening;
- extended hospital stays;
and far more!
There can also be less visible consequences such as lost revenue and reputational damage.
This now changes the decision-making process behind purchasing a diagnostics analyser.
A laboratory director may initially ask:
“How much does the molecular analyser cost?”
But hospital management should perhaps also ask:
“What would a six-month C. auris outbreak cost this institution?”
The answers may change the investment calculation considerably.
What Does the Recent U.S. Spread Tell Us?
As of August 2026, there have been several reports that C.Auris spread across 23 states.
The United States provides a useful warning because C. auris went from being virtually unknown to becoming an established healthcare-associated threat in less than a decade.
The first U.S. case was reported in 2016.
- By 2024, the CDC recorded 6,304 clinical cases in a single year.
- Importantly, the CDC says the rate of increase has slowed since 2022.
So the situation should not be described inaccurately as uncontrolled exponential growth.
But cases continue to rise nationally, transmission continues in some geographical areas, and C. auris has appeared in new areas.
There is also some encouraging evidence.
Early action matters.
And early action depends partly on knowing what is there.
Why Vivalytic May Be Worth Considering Beyond Candida Auris.

There is another important procurement consideration for Vivalytic.
A healthcare organisation does not necessarily need to purchase a molecular analyser exclusively for C. auris.
- Vivalytic is a multi-application molecular diagnostic platform.
Its broader portfolio includes assays that address:
- Respiratory infections, including SARS-CoV-2, Influenza A/B, RSV and Bordetella;
- Gastrointestinal infections, including Clostridioides difficile, Norovirus and Rotavirus;
- Sexually transmitted infections, including 10 STI pathogens in one test including Mycoplasma and Ureaplasma;
- Nosocomial infections, including MRSA/SA and Candida auris; and
- Bacterial meningitis, covering 6 pathogens.
That can fundamentally change the business case.
So instead of asking:
“Do we perform enough Candida auris tests to justify a molecular analyser?”
a laboratory can ask:
“How many of our molecular diagnostic requirements could potentially be addressed using the same platform?”
That is a much more useful procurement question.
What Should Hospitals Consider Before Investing in Vivalytic?
Hospital administrators, laboratory managers and infection-control teams should evaluate the complete diagnostic pathway rather than focusing only on the instrument specification.
Questions worth asking include:
- Has C. auris been detected within our region or referral network?
- Which patients within our facility have the greatest colonisation risk?
- Do we currently screen patients for C. auris?
- Where are those samples processed?
- What is our real sample-to-result turnaround time?
- What precautions are required while we wait?
- How much does precautionary isolation cost?
- What would happen operationally if transmission occurred within one of our wards?
- Could we perform appropriate PCR screening locally?
- What training would laboratory personnel require?
- How reliably can cartridges and specimen-collection materials be supplied?
- What technical and after-sales support is available?
- How would positive results be communicated to infection-control teams?
- Which additional molecular tests could we perform on the same analyser?
- What is the total cost of ownership compared with our current referral-testing pathway?
- What could a significant C. auris outbreak cost our institution?
These questions turn the discussion from:
“Should we buy another laboratory machine?”
into:
“What diagnostic and infection-control capability does our institution actually need?”
Is Your Hospital or Laboratory Prepared for Candida Auris?
If your hospital, diagnostic laboratory or healthcare organisation is reviewing its Candida auris screening, infection-control diagnostics or wider molecular diagnostic capacity, MediDiagAfrica can provide further information about the Bosch Vivalytic platform and Vivalytic C. auris assay.
Bosch notes that product availability can vary between markets. Healthcare organisations should therefore confirm the regulatory status, intended use and availability of individual assays within their country before procurement.
Bosch Vivalytic official website
This article is intended primarily for healthcare and laboratory professionals. It provides general educational and product information and should not replace clinical guidance, local infection-control protocols, public-health recommendations or professional medical judgement.
